J. K. Lim

Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy.

G. Tricot, S. Stass, R. Malone, 1999, Journal of biotechnology.

Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2.

M. Borad, D. V. Von Hoff, D. Northfelt, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human Vgamma2Vdelta2 T cells contain cytoplasmic RANTES.

V. Lukyanenko, R. Paca, C. Pauza, 2006, International immunology.